News

Akorn said that this approval is the company’s first lyophilized product approval for manufacture in its Decatur, Illinois production facility. Akorn has invested approximately $23 million in a

As a result, Albany Molecular Research (AMRI) will receive a $1.5 million milestone payment from Bristol-Myers Squibb Company for the nomination of this clinical candidate, marking the third

The company said that it is reaffirming its adjusted diluted earnings per share (EPS) guidance for 2008, 2009 and 2010 of $0.47 to $0.53, $0.90 to $1.10 and

The alliance is based on discoveries from a collaboration between Arbor Vita (AVC) and NoNO of Toronto, and will explore the use of the companies’ NA-1 compound as

North American Scientific said that the proceeds from the sale of this product line will provide the company with important non-dilutive capital to invest in ongoing operations. John

Finfacts reported that the Minister for Finance, Brian Lenihan has announced that Boston Scientific will invest E50m, with the support of IDA Ireland, in strategic R&D at its

Mr Vaters joins Orthofix after almost four years as a senior executive at Inamed, where he was executive vice president, CFO and head of strategy and corporate development.

The first study has demonstrated a high degree of overall concordance – 95% – between central immunohistochemistry (IHC) and quantitative RT-PCR using Oncotype DX for determining HER2 status.

The randomized, double-blind study evaluated 130 migraine patients. Patients were not on prophylaxis and received 2.5 to 45mg of COL-144 or placebo as an intravenous infusion over 20